August 05, 2019
Imprimis Pharmaceuticals has lost its bid in California federal court to overturn a $48,500 jury award in a case brought by Allergan USA Inc. accusing its rival of using false advertisements to trick doctors into thinking its eye-treatment drugs used FDA-approved ingredients.
July 11, 2019
A California federal court on Thursday handed a partial win to Allergan USA Inc. by blocking the compound drugmaker Imprimis Pharmaceuticals from selling medications under certain conditions, though the judge limited the order's scope to the Golden State.
May 16, 2019
A California federal jury on Thursday ordered Imprimis Pharmaceuticals to pony up just $48,500 to competitor Allergan after finding the compound drug company cost Allergan business by using false advertisements to trick doctors into thinking its eye-treatment drugs used FDA-approved ingredients — far short of the millions Allergan sought.
May 15, 2019
Imprimis Pharmaceuticals cost competitor Allergan thousands of prescriptions and millions in profits when it lied to consumers that its eye-treatment drugs used FDA-approved ingredients, a California federal jury heard during closing arguments Wednesday, in a case in which the trial judge has already found that Imprimis falsely advertised its treatments.
November 13, 2018
A California federal judge on Tuesday ordered Imprimis Pharmaceuticals Inc. to pay $50,000 in attorneys' fees to Allergan USA Inc. as sanctions for violating discovery orders in a false advertising case, which is $100,000 less than what Allergan had requested.
October 05, 2018
The "unreasonable and excessive" fees Allergan USA Inc. is requesting from Imprimis Pharmaceuticals Inc. for that company's failure to comply with discovery orders in a closely watched false advertising suit came from having "overstaffed and over-worked" a simple sanctions motion, the compounding company told a California federal court.
September 10, 2018
A California federal judge has sanctioned Imprimis Pharmaceuticals Inc. for the second time after it violated a discovery order in a closely watched false advertising suit brought by Allergan USA Inc., ordering the drug compounder to provide the withheld documents and pay attorneys' fees.
July 31, 2018
Allergan USA Inc. urged a California federal court Monday to sanction Imprimis Pharmaceuticals Inc. for violating a discovery order in a false advertising case by refusing to hand over documents in the time period set out by the court and then unilaterally setting criteria for what it had to hand over.
January 16, 2018
The latest warning letters from the U.S. Food and Drug Administration are giving new ammunition to Allergan Inc. in its high-stakes battle with a rival drug company and putting a Chinese drugmaker on notice of "life-threatening" risks posed by its manufacturing practices.
January 11, 2018
Allergan USA Inc. on Wednesday urged a California federal court to shoot down false advertising counterclaims brought by drug compounder Imprimis Pharmaceuticals Inc., arguing that it's factually true that its dry-eye medication Restasis is U.S. Food and Drug Administration-approved.